Pacific RxTracts - June 2025

Articles: Atzumi Receives FDA Approval as First Nasal Powder DHE for Migraine Treatment IMAAVY: First and Only FDA-approved Neonatal Fc Receptor Inhibitor for gMG New Prophylactic Treatment Approved for Hemophilia A or B, With or Without Factor Inhibitors Cytisinicline: The Next Smoking Cessation Aid FDA Approves Dupilumab for the Management of Chronic Spontaneous Urticaria Study Shows Promise in Combining Behavioral Treatment with Phentermine Metformin for Osteoarthritis A New Direction in Atopic Dermatitis Treatment Orforglipron: A Potential Oral Alternative to Injectable GLP-1 Agonists Beyond GLP-1s: MariTide’s Dual Mechanism in Weight Loss Therapy Atrasentan Gains FDA Approval to Combat Proteinuria in Primary IgA Nephropathy Fluoroquinolones and Increased Risk of Suicide? Baloxavir Offers a Promising New Indication in Reducing Influenza Transmission First of its Kind Antibiotic Shows Promise in Treating Uncomplicated Gonorrhea Tavapadon: A Promising New Therapy for Parkinson’s Disease Possible Dementia Protective Method by Herpes Zoster Vaccine From Risk to Resolution: Mitigating Drug Interactions in Cancer Treatment Combination Therapy In HER-2 Positive Cancer Treatment